| Literature DB >> 29270513 |
Xiaohong Fan1, Sahir Kalim2, Wenling Ye1, Sophia Zhao2, Jie Ma1, Sagar U Nigwekar2, Kevin E Chan2, Jie Cui2, Jianfang Cai1, Liang Wang3, Wei Heng4, Yali Zhou5, Ying Sun1, Rui Cui1, Wei Zhang1, Baobao Wang1, Qing Dai3, Xuewang Li1, Ravi Thadhani2, Xuemei Li1.
Abstract
INTRODUCTION: Urinary stone disease (USD) is associated with cardiovascular disease (CVD) in Western populations. However, the prevalence and relationship between USD and CVD risk have not been fully examined in the Chinese population.Entities:
Keywords: arterial stiffness; cardiovascular risk; chronic kidney disease; hypertension; peripheral arterial disease; urinary stone disease
Year: 2017 PMID: 29270513 PMCID: PMC5733875 DOI: 10.1016/j.ekir.2017.06.001
Source DB: PubMed Journal: Kidney Int Rep ISSN: 2468-0249
Figure 1Flowchart of study population recruitment.
Characteristics of participants according to the presence of USD
| Variable | USD present | ||
|---|---|---|---|
| Yes (n = 582) | No (n = 9699) | ||
| Age, yr | 56.4 ± 9.8 | 55.3 ± 10.0 | 0.01 |
| Men, % | 64.8 | 46.1 | <0.001 |
| Current or past smoker, % | 47.1 | 34.3 | <0.001 |
| BMI, kg/m2 | 26.3 ± 3.8 | 26.3 ± 3.7 | 0.90 |
| Serum glucose, mmol/l | 6.4 ± 1.7 | 6.3 ± 1.8 | 0.25 |
| Serum sodium, mmol/l | 141.3 ± 2.0 | 141.3 ± 2.0 | 0.77 |
| Serum calcium, mmol/l | 2.3 ± 0.1 | 2.3 ± 0.1 | 0.94 |
| Serum phosphorus, mmol/l | 1.1 ± 0.2 | 1.2 ± 0.2 | <0.001 |
| Serum uric acid, μmol/l | 301.7 ± 88.6 | 279.9 ± 80.5 | <0.001 |
| Triglycerides, mmol/l | 1.5 ± 1.3 | 1.5 ± 1.5 | 0.92 |
| LDL-C, mmol/l | 3.0 ± 0.8 | 3.0 ± 0.8 | 0.38 |
| Serum hsCRP, mg/l | 1.0 (0.5−2.1) | 0.9 (0.4−1.8) | 0.02 |
| Hemoglobin, g/l | 151.5 ± 15.0 | 148.2 ± 15.6 | <0.001 |
| Diabetes, % | 23.2 | 20.4 | 0.12 |
Sex, smoking status, and diabetes are expressed as proportions. The remaining data are expressed as mean ± SD or median (interquartile range).
BMI, body mass index; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; USD, urinary stone disease.
Associations of urinary stone disease with risk factors of cardiovascular disease
| Dichotomous outcomes | USD present | Unadjusted OR (95% CI) | Adjusted OR (95% CI) | |
|---|---|---|---|---|
| Yes (n = 582) | No (n = 9699) | |||
| HTN | 449 (77.3) | 6800 (70.3) | 1.44 (1.18−1.75) | 1.32 (1.08−1.62) |
| CKD | 118 (20.6) | 1056 (11.0) | 2.09 (1.69−2.59) | 2.11 (1.70−2.62) |
| eGFR (<60 ml/min/1.73 m2) | 12 (2.1) | 116 (1.2) | 1.74 (0.95−3.17) | 1.75 (0.933.29) |
| ACR (≥30 mg/g) | 114 (19.9) | 996 (10.4) | 2.14 (1.73−2.66) | 2.17 (1.74−2.69) |
| Framingham CVD risk score (>20%) | 203 (41.2) | 2701 (31.7) | 1.51 (1.26−1.82) | 1.14 (0.93−1.41) |
| baPWV (≥18 m/s) | 131 (22.9) | 1789 (18.8) | 1.28 (1.05−1.57) | 1.24 (1.01−1.52) |
| PAD | 34 (5.9) | 372 (3.9) | 1.55 (1.08−2.23) | 1.50 (1.04−2.16) |
ACR, albumin-to-creatinine ratio; baPWV, brachial-ankle pulsewave velocity; CI, confidence interval; CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimate glomerular filtration rate; HTN, hypertension; OR, odds ratio; PAD, peripheral artery disease; USD, urinary stone disease.
Outcomes are expressed as number (proportion); the calculated proportion may be based on slightly different sample sizes because of missing values for a particular outcome.
Adjusted for sex, smoking, uric acid, hemoglobin, and phosphate.
Figure 2The prevalence of urinary stone disease in study participants grouped into quartiles by various outcomes measures. ABI, ankle−brachial index; ACR, albumin-to-creatinine ratio; baPWV, brachial-ankle pulsewave velocity; eGFR, estimated glomerular filtration rate.